Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 07 - 05 tags : Fda save search
THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAI'S BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
Published: 2022-07-05 (Crawled : 00:00) - prnewswire.com
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 1.98%
H: 1.73%
C: 1.35%
fda disease alzheimer's application grants license approval review lecanemab
Amylyx Pharmaceuticals Announces FDA Plan to Reconvene Advisory Committee to Review AMX0035 NDA for the Treatment of ALS on September 7, 2022
Published: 2022-07-05 (Crawled : 14:00) - biospace.com/
AMLX A | $1.945 -1.77% -1.8% 1.5M
|
|
| O: 16.23%
H: 2.39%
C: -13.83%
amx0035 treatment fda als review
Teva Uses the Agilent TRS100 to Achieve Regulatory Milestone for Content Uniformity Testing with the FDA
Published: 2022-07-05 (Crawled : 13:00) - biospace.com/
A | $139.2 3.95% -0.14% 2M
|
Health Technology
|
| O: -0.86%
H: 2.48%
C: 2.39%
trs100 fda milestone
Titan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene Implant
Published: 2022-07-05 (Crawled : 13:00) - biospace.com/
TTNP | $7.05 0.57% 0.57% 1.1K
|
Health Technology
|
| O: 0.83%
H: 15.56%
C: 12.77%
fda clearance implant application
Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
Published: 2022-07-05 (Crawled : 13:00) - biospace.com/
VRTX | $404.93 1.25% 1.43% 1.1M
|
Health Technology
|
| O: -0.49%
H: 1.41%
C: 1.07%
vx-880 treatment fda lifted trial diabetes phase 1 clinical hold
Ra Medical Systems Receives FDA 510(k) Clearance for the DABRA 2.0 Catheter
Published: 2022-07-05 (Crawled : 12:00) - biospace.com/
RMED | $0.594 0.0% 78K
|
Health Technology
|
| O: 44.01%
H: 32.58%
C: -3.35%
fda clearance
Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
Published: 2022-07-05 (Crawled : 12:00) - globenewswire.com
DYN | $25.44 2.29% 2.24% 810K
|
Health Technology
|
| O: 0.0%
H: 17.36%
C: 17.22%
dyne-251 treatment fda clearance application therapeutics duchenne
ANeuroTech receives positive feedback from the FDA for its pivotal Phase IIIb development programme for ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder
Published: 2022-07-05 (Crawled : 10:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.76%
H: 0.0%
C: 0.0%
ant-01 fda drug positive major depressive disorder
Breakthrough radiology AI provider annalise.ai appoints proven global healthcare leader as CEO, officially launches US team following FDA clearances
Published: 2022-07-05 (Crawled : 05:00) - prnewswire.com
HCA 4 | $319.43 2.94% 0.0% 1.2M
|
Health Services
|
| O: -0.99%
H: 0.16%
C: -0.43%
fda
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.